Autolus Therapeutics plc American Depositary Share (AUTL) Stock
Key stats
- Market cap
- $328.71M
- Price / Earnings ratio
- -1.3x
- EPS (TTM)
- -$1.06
- Volume
- Loading
- 52-week high
- $2.58
- 52-week low
- $1.12
Source: third-party data provider, as of November 13, 2026
Compare with AUTL
Recent news

All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
AUTL

Autolus Therapeutics Q2 Earnings Call Highlights
Autolus Therapeutics Q2 Earnings Call Highlights
AUTL

3 Cancer Stocks to Watch as Oncology Innovation Accelerates
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
AUTL

New Strong Sell Stocks for January 22nd
New Strong Sell Stocks for January 22nd
AUTL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 27.72
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.12
- MACD histogram
- -0.01
- SMA 50
- $1.74
- Price below SMA 50
- EMA 50
- $1.65
- Price below EMA 50
- SMA 200
- $1.66
- Price below SMA 200
- EMA 200
- $1.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
AUTL

Autolus Therapeutics Q2 Earnings Call Highlights
Autolus Therapeutics Q2 Earnings Call Highlights
AUTL

3 Cancer Stocks to Watch as Oncology Innovation Accelerates
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
AUTL

New Strong Sell Stocks for January 22nd
New Strong Sell Stocks for January 22nd
AUTL

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
AUTL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Christian Martin Itin Ph.D. | CEO & Director | 1964 |
| Mr. Robert F. Dolski | Senior VP & CFO | 1971 |
| Mr. Christopher Vann | Senior VP & COO | 1965 |
| Dr. Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer | 1972 |
| Mr. Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | 1980 |
| Ms. Miranda Neville | Senior VP & Chief Technology Officer | 1975 |
| Mr. Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary | 1976 |
| Mr. Alexander Swan | Senior VP & Chief Human Resources Officer | 1965 |
| Dr. Christopher Williams Ph.D. | Senior VP & Chief Business Development Officer | 1980 |
| Dr. Matthias Will M.D. | Senior VP & Chief Development Officer | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 27.72
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.12
- MACD histogram
- -0.01
- SMA 50
- $1.74
- Price below SMA 50
- EMA 50
- $1.65
- Price below EMA 50
- SMA 200
- $1.66
- Price below SMA 200
- EMA 200
- $1.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $10.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +20.5 | -16.0 | -17.8 | -12.7 |



